180 Wealth Advisors LLC Has $533,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

180 Wealth Advisors LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,150 shares of the company’s stock after selling 107 shares during the period. 180 Wealth Advisors LLC’s holdings in Zoetis were worth $533,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ZTS. Thrive Wealth Management LLC increased its stake in shares of Zoetis by 8.6% during the 1st quarter. Thrive Wealth Management LLC now owns 6,161 shares of the company’s stock worth $1,043,000 after purchasing an additional 487 shares during the last quarter. Chesley Taft & Associates LLC increased its holdings in shares of Zoetis by 0.7% during the 1st quarter. Chesley Taft & Associates LLC now owns 60,059 shares of the company’s stock valued at $10,163,000 after acquiring an additional 445 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Zoetis by 7.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 244,348 shares of the company’s stock valued at $41,346,000 after acquiring an additional 17,488 shares in the last quarter. Procyon Advisors LLC raised its stake in shares of Zoetis by 20.2% in the 1st quarter. Procyon Advisors LLC now owns 5,423 shares of the company’s stock valued at $918,000 after acquiring an additional 911 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC lifted its holdings in Zoetis by 4.3% in the 1st quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock worth $20,478,000 after purchasing an additional 5,035 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS stock traded down $0.56 during mid-day trading on Friday, reaching $175.90. The stock had a trading volume of 694,844 shares, compared to its average volume of 2,941,856. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The firm has a market cap of $80.26 billion, a PE ratio of 33.81, a P/E/G ratio of 2.65 and a beta of 0.88. The firm’s 50 day simple moving average is $167.68 and its 200 day simple moving average is $178.94. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. Zoetis’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business earned $1.31 earnings per share. On average, analysts forecast that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ZTS shares. The Goldman Sachs Group dropped their price target on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday, May 6th. Barclays decreased their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. HSBC decreased their target price on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Finally, Stifel Nicolaus dropped their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 30th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.